Background Percutaneous left atrial appendage closure (LAAC) is noninferior to vitamin K
antagonists (VKAs) for preventing atrial fibrillation (AF)–related stroke. However, direct oral …

Abstract Background The PRAGUE-17 (Left Atrial Appendage Closure vs Novel
Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage …

Background: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …

Electronic databases were searched from inception until June 23, 2020, for RCTs comparing
LAAC versus OAC in nonvalvular AF. Outcomes were all-stroke/systemic embolism (SE) …

Background The effectiveness of vitamin K antagonist (VKA) versus placebo and antiplatelet
therapy (APT) is well established for stroke prevention in atrial fibrillation (AF). Non-vitamin K …

Objectives: The purpose of this study was to compare the relative risk of major bleeding with
left atrial appendage (LAA) closure compared with long-term warfarin therapy. Background …

Abstract Background: The PROTECT AF (WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …

Objectives This study sought to investigate clinical outcomes associated with left atrial
appendage occlusion (LAAO) versus direct oral anticoagulants (DOACs) in patients with …

Background: Left atrial appendage closure (LAAC) was approved by the US Food and Drug
Administration (FDA) as a stroke prevention alternative to warfarin for patients with …

Importance While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin
is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and …